德展健康(000813.SZ):過户完成、新疆國資委成為公司實控人
格隆匯7月28日丨德展健康(000813.SZ)公佈,2021 年7 月28 日,公司收到中國證券登記結算有限責任公司出具的《證券過户登記確認書》,美林控股及其一致行動人凱世富樂9號協議轉讓給凱迪投資的167,886,987 股股份已於2021年7月27日完成了過户登記手續,股份性質為無限售流通股。
此次股份過户完成後,凱迪投資持有公司409,748,445股股份,佔公司總股本的18.28%。凱迪投資及其一致行動人持有上市公司共計536,589,758股股份,占上市公司總股本的 23.94%。凱迪投資成為上市公司控股股東,新疆國資委成為公司實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.